The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Transcriptional expression of Bcl-2 as predictive of response to neoadjuvant chemotherapy with trastuzumab in HER2-positive ER-positive breast cancer patients.
Maki Tanioka
No relevant relationships to disclose
Kazuko Sakai
No relevant relationships to disclose
Tamotsu Sudo
No relevant relationships to disclose
Toshiko Sakuma
No relevant relationships to disclose
Kouichi Hirokaga
No relevant relationships to disclose
Shintaro Takao
No relevant relationships to disclose
Hironobu Minami
Consultant or Advisory Role - Chugai Pharma
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Shunichi Negoro
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose
Kazuto Nishio
No relevant relationships to disclose